Beyond sequence variation: assessment of copy number variation in adult glioblastoma through targeted tumor somatic profiling

Samantha N. McNulty, Catherine E. Cottrell, Katinka A. Vigh-Conrad, Jamal H. Carter, Jonathan W. Heusel, George Ansstas, Sonika Dahiya

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Glioblastoma is the most common primary malignancy of the adult central nervous system. Gliomagenesis involves a complex range of alterations, including sequence changes, copy number variations (CNVs), and epigenetic modifications, that have clinical implications for disease classification and prognosis. Thus, multiple testing modalities are required to support a complete diagnostic workup. The goal of this study was to streamline the multipart workflow by predicting both sequence changes and CNVs (specifically EGFR amplifications) from a single next-generation sequencing (NGS) test. Eighty-six primary and secondary glioblastomas were submitted for clinical NGS to report sequence variants from a concise panel of cancer-relevant genes. Most specimens underwent concomitant testing by methylation-specific polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization. Using data generated during the course of clinical testing, we found that NGS-based variant predictions were concordant with immunohistochemistry and fluorescence in situ hybridization for IDH mutation and EGFR amplification status, respectively. We also noted that EGFR amplifications correlated with polysomy of chromosome 7, 19, and 20, and loss of PTEN and CDKN2A. EGFR-unamplified cases had lower rates of chromosome 7 polysomy, and PTEN and CDKN2A loss, but more CNVs overall. TP53, NF1, ATRX, and PDGFRA mutations were nearly exclusive to specimens without EGFR amplification. EGFR amplification was not associated with longer progression-free survival in this cohort, but amplifications were enriched in a group with slightly longer overall survival despite radiographic evidence of disease progression. Further study is needed to explore the mechanisms responsible for noted patterns of co-occurring variants and to correlate them with specific clinical outcomes.

Original languageEnglish (US)
Pages (from-to)170-181
Number of pages12
JournalHuman Pathology
Volume86
DOIs
StatePublished - Apr 1 2019
Externally publishedYes

Fingerprint

Chromosomes, Human, Pair 7
Glioblastoma
Fluorescence In Situ Hybridization
Immunohistochemistry
Chromosomes, Human, Pair 20
Chromosomes, Human, Pair 19
Mutation
Workflow
Neoplasm Genes
Epigenomics
Methylation
Disease-Free Survival
Disease Progression
Neoplasms
Central Nervous System
Polymerase Chain Reaction

Keywords

  • Clinical sequencing
  • Copy number variation
  • EGFR amplification
  • Glioblastoma
  • Next-generation sequencing

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Beyond sequence variation : assessment of copy number variation in adult glioblastoma through targeted tumor somatic profiling. / McNulty, Samantha N.; Cottrell, Catherine E.; Vigh-Conrad, Katinka A.; Carter, Jamal H.; Heusel, Jonathan W.; Ansstas, George; Dahiya, Sonika.

In: Human Pathology, Vol. 86, 01.04.2019, p. 170-181.

Research output: Contribution to journalArticle

McNulty, Samantha N. ; Cottrell, Catherine E. ; Vigh-Conrad, Katinka A. ; Carter, Jamal H. ; Heusel, Jonathan W. ; Ansstas, George ; Dahiya, Sonika. / Beyond sequence variation : assessment of copy number variation in adult glioblastoma through targeted tumor somatic profiling. In: Human Pathology. 2019 ; Vol. 86. pp. 170-181.
@article{54689b7d81f64f4d90c1b2bf5c5e6059,
title = "Beyond sequence variation: assessment of copy number variation in adult glioblastoma through targeted tumor somatic profiling",
abstract = "Glioblastoma is the most common primary malignancy of the adult central nervous system. Gliomagenesis involves a complex range of alterations, including sequence changes, copy number variations (CNVs), and epigenetic modifications, that have clinical implications for disease classification and prognosis. Thus, multiple testing modalities are required to support a complete diagnostic workup. The goal of this study was to streamline the multipart workflow by predicting both sequence changes and CNVs (specifically EGFR amplifications) from a single next-generation sequencing (NGS) test. Eighty-six primary and secondary glioblastomas were submitted for clinical NGS to report sequence variants from a concise panel of cancer-relevant genes. Most specimens underwent concomitant testing by methylation-specific polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization. Using data generated during the course of clinical testing, we found that NGS-based variant predictions were concordant with immunohistochemistry and fluorescence in situ hybridization for IDH mutation and EGFR amplification status, respectively. We also noted that EGFR amplifications correlated with polysomy of chromosome 7, 19, and 20, and loss of PTEN and CDKN2A. EGFR-unamplified cases had lower rates of chromosome 7 polysomy, and PTEN and CDKN2A loss, but more CNVs overall. TP53, NF1, ATRX, and PDGFRA mutations were nearly exclusive to specimens without EGFR amplification. EGFR amplification was not associated with longer progression-free survival in this cohort, but amplifications were enriched in a group with slightly longer overall survival despite radiographic evidence of disease progression. Further study is needed to explore the mechanisms responsible for noted patterns of co-occurring variants and to correlate them with specific clinical outcomes.",
keywords = "Clinical sequencing, Copy number variation, EGFR amplification, Glioblastoma, Next-generation sequencing",
author = "McNulty, {Samantha N.} and Cottrell, {Catherine E.} and Vigh-Conrad, {Katinka A.} and Carter, {Jamal H.} and Heusel, {Jonathan W.} and George Ansstas and Sonika Dahiya",
year = "2019",
month = "4",
day = "1",
doi = "10.1016/j.humpath.2018.12.004",
language = "English (US)",
volume = "86",
pages = "170--181",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Beyond sequence variation

T2 - assessment of copy number variation in adult glioblastoma through targeted tumor somatic profiling

AU - McNulty, Samantha N.

AU - Cottrell, Catherine E.

AU - Vigh-Conrad, Katinka A.

AU - Carter, Jamal H.

AU - Heusel, Jonathan W.

AU - Ansstas, George

AU - Dahiya, Sonika

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Glioblastoma is the most common primary malignancy of the adult central nervous system. Gliomagenesis involves a complex range of alterations, including sequence changes, copy number variations (CNVs), and epigenetic modifications, that have clinical implications for disease classification and prognosis. Thus, multiple testing modalities are required to support a complete diagnostic workup. The goal of this study was to streamline the multipart workflow by predicting both sequence changes and CNVs (specifically EGFR amplifications) from a single next-generation sequencing (NGS) test. Eighty-six primary and secondary glioblastomas were submitted for clinical NGS to report sequence variants from a concise panel of cancer-relevant genes. Most specimens underwent concomitant testing by methylation-specific polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization. Using data generated during the course of clinical testing, we found that NGS-based variant predictions were concordant with immunohistochemistry and fluorescence in situ hybridization for IDH mutation and EGFR amplification status, respectively. We also noted that EGFR amplifications correlated with polysomy of chromosome 7, 19, and 20, and loss of PTEN and CDKN2A. EGFR-unamplified cases had lower rates of chromosome 7 polysomy, and PTEN and CDKN2A loss, but more CNVs overall. TP53, NF1, ATRX, and PDGFRA mutations were nearly exclusive to specimens without EGFR amplification. EGFR amplification was not associated with longer progression-free survival in this cohort, but amplifications were enriched in a group with slightly longer overall survival despite radiographic evidence of disease progression. Further study is needed to explore the mechanisms responsible for noted patterns of co-occurring variants and to correlate them with specific clinical outcomes.

AB - Glioblastoma is the most common primary malignancy of the adult central nervous system. Gliomagenesis involves a complex range of alterations, including sequence changes, copy number variations (CNVs), and epigenetic modifications, that have clinical implications for disease classification and prognosis. Thus, multiple testing modalities are required to support a complete diagnostic workup. The goal of this study was to streamline the multipart workflow by predicting both sequence changes and CNVs (specifically EGFR amplifications) from a single next-generation sequencing (NGS) test. Eighty-six primary and secondary glioblastomas were submitted for clinical NGS to report sequence variants from a concise panel of cancer-relevant genes. Most specimens underwent concomitant testing by methylation-specific polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization. Using data generated during the course of clinical testing, we found that NGS-based variant predictions were concordant with immunohistochemistry and fluorescence in situ hybridization for IDH mutation and EGFR amplification status, respectively. We also noted that EGFR amplifications correlated with polysomy of chromosome 7, 19, and 20, and loss of PTEN and CDKN2A. EGFR-unamplified cases had lower rates of chromosome 7 polysomy, and PTEN and CDKN2A loss, but more CNVs overall. TP53, NF1, ATRX, and PDGFRA mutations were nearly exclusive to specimens without EGFR amplification. EGFR amplification was not associated with longer progression-free survival in this cohort, but amplifications were enriched in a group with slightly longer overall survival despite radiographic evidence of disease progression. Further study is needed to explore the mechanisms responsible for noted patterns of co-occurring variants and to correlate them with specific clinical outcomes.

KW - Clinical sequencing

KW - Copy number variation

KW - EGFR amplification

KW - Glioblastoma

KW - Next-generation sequencing

UR - http://www.scopus.com/inward/record.url?scp=85062683733&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062683733&partnerID=8YFLogxK

U2 - 10.1016/j.humpath.2018.12.004

DO - 10.1016/j.humpath.2018.12.004

M3 - Article

C2 - 30594748

AN - SCOPUS:85062683733

VL - 86

SP - 170

EP - 181

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

ER -